Last reviewed · How we verify
NCT06002022: REBECCA-QoL
Evaluation of Improvements in Patient-reported Quality of Life
NA trial testing REBECCA system (smartwatch + mobile app use) in Breast Cancer in 110 participants. Currently enrolling.
28 July 2025
Quick facts
| Lead sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 110 |
| Start date | 1 January 2024 |
| Primary completion | 28 July 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- REBECCA system (smartwatch + mobile app use)
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Quality of Life — all drugs for Quality of Life →
- Physical Activity — all drugs for Physical Activity →
- Sleep Quality — all drugs for Sleep Quality →
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Who can join
Adults 18 to 75, female only, with Breast Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Local intervention trial for the evaluation of improvements in patient-reported Quality of Life and treatment satisfaction, in breast cancer patients (BCP), as a result of flexible treatment planning supported by REBECCA-collected real-world data, in comparison with standard care
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06002022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Fundación para la Investigación del Hospital Clínico de Valencia trials
Trials by the same sponsor.
- NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
- NCT07291999 — Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry · active not recruiting
- NCT06655532 — Effects of an Exercise Program in Women Over 60 yr. With HFpEF and Sarcopenia on Functional Capacity and Quality of Life · NA · not yet recruiting
- NCT06578078 — A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · recruiting
- NCT06578520 — Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06002022 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación para la Investigación del Hospital Clínico de Valencia
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06002022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing